If the Food and Drug Administration’s final rule placing laboratory developed tests (LDTs) under its regulatory purview goes through as planned, almost half of the labs that now make the tests will stop producing them, according to one of the leading laboratory organizations.
Lab Association Asks Congress To Kill FDA’s Final Rule On LDTs
In a letter to US lawmakers, the Association for Diagnostics and Laboratory Medicine says the FDA’s final rule regulating lab-developed tests will stifle innovation and that Congress needs to step in and stop it.
More from Regulation
More from Policy & Regulation
• By
With the support of AIM-MASH AI Assist only one pathologist is needed to reliably make a histology assessment of inflammatory liver disease to decide whether patients should be included in MASH clinical trials.
• By
The US FDA has issued an early alert about the CVAC system from Calyxo, which urologists use in removing urinary stones.
• By
EU medtech trade associations present detailed arguments for the European Commission’s 'targeted evaluation' of medtech regulations, highlighting the need for immediate course correction.